Post Profile

PharmaMar and Boryung Pharm sign a licensing agreement for Aplidin® (plitidepsin) in Korea

(Pharmamar) PharmaMar (MSE:PHM) has announced today a licensing agreement with Boryung Pharm to commercialize the marine-derived anticancer drug Aplidin® (plitidepsin) in South Korea.
read more


Related Posts

Phase 3 trial with PM1183 in OC continues on the basis of positive recommendation by IDMC

Academics / General Science : Science Codex

PharmaMar (MSE:PHM) announced today that the Independent Data Monitoring Committee (IDMC) has notified the Company of its recommendation that the Phase III (CORAIL) trial currently under way with PM1183 in platinum-resistant ovarian...

Zero Gravity Solutions, Inc.’s Wholly-Owned Subsidiary, BAM Agricultural Solutions, Inc., Signs an Exclusive Distribution Agreement for the Republic of Paraguay

Technology : Venture Beat

PRESS RELEASE: Zero Gravity Solutions, Inc. ("ZGSI" or the "Company") (Pink Sheets: ZGSI), an agricultural biotechnology public company commercializing its technology derived from and designed for Space with significant applications...

PharmaMar presents results at EORTC-NCI-AACR to highlight a pipeline of targeted therapies

Academics / General Science : Science Codex

PharmaMar results for antitumoral compounds and their mechanism of action at EORTC-NCI-AACR emphasize an innovative pipeline of targeted therapies Targeting of eEF1A2 by antitumor drug Aplidin® reveals novel mechanism of action driv...

Sylentis reports positive Phase II results with SYL1001 in treating ocular pain

Academics / General Science : Science Codex

Sylentis, a pharmaceutical company in the PharmaMar Group (MSE:PHM) and a pioneer in the research and development of new drugs based on gene silencing (interference RNA, RNAi), has presented the results of two Phase II dose-finding ...

Positive results from the Phase I study of plitidepsin in combination for MM

Academics / General Science : Science Codex

PharmaMar (MSE:PHM) announces the positive results from a Phase I study of plitidepsin in combination with bortezomib and dexamethasone in patients with relapsed and/or refractory multiple myeloma. Dr María Victoria Mateos, MD of th...


Copyright © 2016 Regator, LLC